Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials

Trials

127 trials with extracted results or outcome data. Registered trials without results are listed on the molecule pages and on the timeline.

Data cut 12 November 2026
TrialMolecule(s)PopulationnData
ACCESS (phase 2b)Aleniglipronobesity65arms
ACHIEVE-1Orforglipront2d559arms
ACHIEVE-2 (vs dapagliflozin)Orforglipront2d241arms
ACHIEVE-4OrforglipronT2D at increased CV risk (86 % established CVD, 38 % CKD), t2d2749arms, CVOT
AMPLITUDE-OEfpeglenatideT2D + CVD/CKD4076CVOT
Amycretin oral phase 1Amycretinobesity144arms
Amycretin s.c. phase 1b/2aAmycretinobesity125arms
ATTAIN-1Orforglipronobesity3127arms
ATTAIN-2 (obesity + T2D)Orforglipront2d1613arms
ATTAIN-J (Japan)Orforglipronobesity61arms
ATTAIN-OSA trial 1 / trial 2OrforglipronObstructive sleep apnoea + obesity or overweight (no T2D)712outcomes
BGM0504 phase 2 (China, obesity)BGM0504obesityarms
BGM0504 phase 3 (obesity)BGM0504obesityarms
China Phase II (obesity, non-diabetic)HDM1005obesity243arms
CT-388 phase 2CT-388obesityarms
CT-388-104 (T2D)CT-388t2darms
DREAMS-1Mazdutidet2d320arms
DREAMS-2Mazdutidet2darms
DREAMS-3Mazdutidet2d349arms
EECOH-1Ecnoglutidet2d211arms
EECOH-2Ecnoglutidet2d623arms
ELADLiraglutideMild cognitive impairment + T2D396outcomes
ELIXALixisenatideT2D after ACS6068CVOT
EloraTZP phase 2b (obesity + T2D)EloraTZP, Eloralintide, Tirzepatidet2darms
ENLIGHT Phase IIb (NCT06921486)Efsubaglutide alfa (supaglutide)obesity200arms
ESSENCE (part 1)SemaglutideMASH F2–F3800outcomes
evoke / evoke+SemaglutideEarly Alzheimer's disease3680outcomes
EXSCELExenatideT2D, broad CV risk14752CVOT
FLOWSemaglutideCKD + T2D, T2D + CKD3533CVOT, outcomes
GLORY-1Mazdutideobesityarms
GLORY-2Mazdutideobesityarms
GRADUAL-1 (NCT06728124)Bofanglutide (GZR18)obesity640arms
HARBOR-1 (HRS-7535-303, NCT06904105)HRS-7535obesity556arms
Harmony OutcomesAlbiglutideT2D + CVD9463CVOT
HDM1002-301HDM1002obesity857arms
HDM1005 phase 2 (T2D)HDM1005t2d220arms
HDM1702 vs Wegovy (bioequivalence)HDM1702obesity462arms
HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600)HRS-4729obesity60arms
HRS-7535 phase 2 (add-on to metformin + SGLT2i)HRS-7535t2d53arms
HRS9531-201 (NCT05881837)Ribupatide (HRS9531)obesity249arms
HRS9531-203 (NCT06054698)Ribupatide (HRS9531)obesityarms
HRS9531-301 (GEMINI-1, NCT06396429)Ribupatide (HRS9531)obesity567arms
HRS9531-T-201 oral ribupatide (NCT06841445)Ribupatide (HRS9531)obesity166arms
IMPACTPemvidutideMASH F2–F3212outcomes
LEADERLiraglutideT2D at high CV risk9340CVOT
LIGHTEN (HS-20094-301)HS-20094obesity604arms
MariTide phase 2 (obesity cohort)MariTideobesity, t2d79arms
MARITIME-CVMariTideObesity with established CVD12800ongoing
MOMENTUMPemvidutideobesity391arms
OASIS 4Semaglutideobesity307arms
Orforglipron CVOTOrforglipronAtherosclerotic CVD, obesity or T2D7140ongoing
OUTSTAND-1 (early T2D, monotherapy)HRS-7535t2d284arms
OUTSTAND-2 (HRS-7535-302, NCT06589765)HRS-7535t2d810arms
PEX168 add-on to metformin phase 3bPEG-loxenatidet2darms
PEX168 monotherapy phase 3aPEG-loxenatidet2d361arms
Phase 2bEfinopegdutideMASH F2–F3386outcomes
Phase 2b CTR20231695Bofanglutide (GZR18)obesity64arms
Phase 2b CTR20232069 (vs semaglutide)Bofanglutide (GZR18)t2d264arms
Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197)PB-119t2d310arms
Phase 3 monotherapy (NCT04504370)PB-119t2d137arms
Phase 3 weight management (ChiCTR1900023428)Beinaglutideobesity282arms
Phase III TG103 + metformin vs dulaglutide (EASD 2026)TG103t2d211arms
PIONEER 6SemaglutideT2D at high CV risk3183CVOT
REBUILDING-1 (RAY1225, NCT06254261)RAY1225obesity172arms
REBUILDING-2 (RAY1225, NCT06893016)RAY1225obesity641arms
REDEFINE 1CagriSemaobesity3417arms
REDEFINE 2CagriSemat2d1206arms
REDEFINE 3CagriSemaObesity + established CVD7101ongoing
REDEFINE 5 (vs semaglutide 2.4 mg)CagriSemaobesity164arms
REDEFINE 9CagriSemaobesityarms
REIMAGINE 1 (early T2D)CagriSemat2d189arms
REIMAGINE 5 (vs tirzepatide 5 mg)CagriSemat2darms
Retatrutide phase 2 (obesity)Retatrutideobesity338arms
Retatrutide phase 2 (T2D)Retatrutidet2d281arms
REWINDDulaglutideT2D, broad CV risk9901CVOT
RGT-075 phase 2bRGT-075obesityarms
Ribupatide in obesity + PMOS (NCT06595797)Ribupatide (HRS9531)obesity158arms
Ribupatide phase 2 (obesity + PMOS)Ribupatide (HRS9531)obesity158arms
Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344)Ribupatide (HRS9531)t2darms
SELECTSemaglutideObesity + established CVD, no diabetes17604CVOT
Shining-1 (T2D)RAY1225t2d231arms
SLIMMEREcnoglutideobesity664arms
SLIMMER-UP-SWITCH (interim)Ecnoglutideobesity163arms
SOLSTICE (NCT06579105)AZD5004 (ECC5004)t2d406arms
SOULSemaglutideT2D + CVD/CKD9650CVOT
STEP 1Semaglutideobesity1961arms
STEP 2Semaglutidet2d1210arms
STEP 9SemaglutideKnee osteoarthritis + obesity407outcomes
STEP UPSemaglutideobesity1407arms
STEP-HFpEFSemaglutideHFpEF + obesity529outcomes
STEP-HFpEF DMSemaglutideHFpEF + obesity + T2D616outcomes
SUMMITTirzepatideHFpEF + obesity731CVOT, outcomes
SUPER 2 (NCT04998032), phase 3 stageEfsubaglutide alfa (supaglutide)t2d171arms
SURMOUNT-1Tirzepatideobesity2539arms
SURMOUNT-2Tirzepatidet2d938arms
SURMOUNT-5 (head-to-head)Tirzepatideobesity751arms
SURMOUNT-MMOTirzepatideObesity, morbidity and mortality15374ongoing
SURMOUNT-OSATirzepatideObstructive sleep apnoea + obesity469outcomes
SURPASS-CVOTTirzepatideT2D + established ASCVD13299CVOT
Survodutide phase 2 (obesity)Survodutideobesity387arms
Survodutide phase 2 MASHSurvodutideMASH F1–F3293outcomes
SUSTAIN-6SemaglutideT2D at high CV risk3297CVOT
SYNCHRONIZE-1Survodutideobesity242arms
SYNCHRONIZE-2 (obesity + T2D)Survodutidet2darms
SYNCHRONIZE-CVOTSurvodutideObesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD), obesity5530arms, CVOT
SYNERGY-NASHTirzepatideMASH F2–F3190outcomes
TG103 phase 3 vs dulaglutide (T2D)TG103t2darms
TRANSCEND-T2D-1 (T2D monotherapy)Retatrutidet2d537arms
TRANSCEND-T2D-2 (vs semaglutide 2 mg)Retatrutidet2darms
TRIUMPH-1Retatrutideobesity584arms
TRIUMPH-1-OSA / TRIUMPH-2-OSARetatrutideObstructive sleep apnoea + obesity (with or without T2D)691outcomes
TRIUMPH-2 (obesity + T2D)Retatrutidet2darms
TRIUMPH-4 (obesity + knee osteoarthritis)Retatrutideobesity148arms
TRIUMPH-4 / TRIUMPH-1-OARetatrutideKnee osteoarthritis + obesity1019outcomes
TRIUMPH-OUTCOMESRetatrutideObesity + CVD10000ongoing
UBT251 phase 2 (obesity)UBT251obesityarms
UBT251 phase 2 (T2D)UBT251t2darms
UBT251 phase 2 obesity China (NCT07177469)UBT251obesity205arms
UBT251 phase 2 T2D China (NCT07163624)UBT251t2d211arms
US phase 2 (NCT06124807)Mazdutideobesity179arms
US Phase 2 (NCT06737042)Bofanglutide (GZR18)obesity326arms
VENTURE (phase 2, s.c.)VK2735obesity36arms
VENTURE-Oral (phase 2)VK2735obesity40arms
VISTA (NCT06579092)AZD5004 (ECC5004)obesity310arms
Zenagamtide s.c. phase 2 (T2D)Amycretint2d38arms
ZUPREME-1Petrelintideobesityarms
ZUPREME-2 (obesity + T2D)Petrelintidet2darms